Conference abstract · 3 Oct 2016
Conference abstractPublished 3 Oct 2016
Synergy between ASH and NASH
The George Washington University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Fatty Liver (hepatosteatosis) is the earliest abnormality in the pathogenesis of Alcoholic Steatohepatitis (ASH) and Non-Alcoholic Steatohepatitis (NASH) and due either to metabolic risk factors associated with chronic alcohol abuse or with insulin resistance and/or metabolic syndrome in the absence of alcohol consumption. When unchecked, both ASH and NASH lead to liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC) and eventual death. A number of common mechanisms contribute to the above various stages of hepatocyte injury including lipotoxicity, endotoxin release, oxidative and ER stress leading to increased pro-inflammatory cytokines that stimulate hepatic fibrogenesis and cirrhosis by activating the quiescent hepatic stellate cells (HSC) into myofibroblasts. Significantly, patients with either ASH or NASH respond favorably to early treatment modalities to reduce hepatic fat accumulation and consequent increased inflammatory signaling and activation of hepatic stellate cells. Although the pathogenic pathways associated with ASH and NASH are seemingly similar, differentiation of the molecular mechanism/s of the pathogenesis of these liver diseases is critical in identifying the unique molecular signatures especially in the early diagnosis of ASH and NASH. Current clinical practice requires the invasive biopsy procedure for the conclusive diagnosis of ASH and NASH. Micro RNAs (miRNAs) are ~22 nucleotide non-coding sequences that bind to the 3'-untranslated region of target transcripts and regulate gene expression by degradation of target mRNAs or inhibition of translation. Emerging studies may prove to establish miRNAs as excellent non-invasive tools for the early diagnosis of various stages of liver diseases.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 29 Jul 2025
NASH: Complex Liver Disease, Emerging Therapies, Multiple Targets
Brief report · 29 May 2025
Biomarkers and Omics for NAFLD/NASH Diagnosis
Editorial · 31 Jan 2025
Radiological Monitoring of Fibrosis in Non-Alcoholic Steatohepatitis (NASH) Using Elastography
Brief report · 29 Jan 2025
NASH: Evolving Diagnostics, Therapeutics, and Precision
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “M. Raj Lakshman”
